Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Melanoma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Newly Diagnosed Glioblastoma 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Lymphoma, Large B-Cell, Diffuse 1Locally Advanced or Metastatic Solid Tumors 1Glioma 1Carcinoma, Merkel Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Carboplatin 8Pemetrexed 6pembrolizumab 5osimertinib 4entinostat 3Paclitaxel 3Gemcitabine 3selpercatinib 2pralsetinib 2durvalumab 2Erlotinib Hydrochloride 2Cisplatin 2taletrectinib 1sotorasib 1repotrectinib 1patritumab 1necitumumab 1napabucasin 1ficlatuzumab 1exemestane 1efineptakin alfa 1cobimetinib 1ceralasertib 1camrelizumab 1atezolizumab 1alectinib 1Vinorelbine 1TNFSF10 protein, human 1Patient Reported Outcome Measures 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Thoracic Neoplasms × efineptakin alfa × Clear all
NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NeoImmuneTech

Phase 1/2 Completed
215 enrolled 30 charts
BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡